bIosimilar of aDalimumab, an European evAluation
NCT05190484 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1050
Last updated 2022-01-13
Summary
The study objective is aimed to describe all country, site, investigator and patient variables that lead to treatment persistence for at least 12 months among patients with rheumatologic and intestinal chronic inflammatory diseases who were switched to FK adalimumab, in order to develop a model to predict persistence at 12 months.
Conditions
Sponsors & Collaborators
-
Fresenius Kabi
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-30
- Primary Completion
- 2023-04-30
- Completion
- 2024-04-30
More Related Trials
-
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
NCT03662919 ·Status: COMPLETED
-
Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis
NCT03110094 ·Status: COMPLETED ·Phase: NA
-
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
NCT01712178 ·Status: COMPLETED ·Phase: PHASE2
-
Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA
NCT03561649 ·Status: COMPLETED ·Phase: NA
-
A Real-world Study of Imraldi® Use
NCT04089514 ·Status: COMPLETED
-
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
NCT03086343 ·Status: COMPLETED ·Phase: PHASE3
-
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
NCT01000441 ·Status: COMPLETED ·Phase: PHASE4
-
A 12-month Real Life Study of IBD Patients Switched From Adalimumab Originator Humira® to One of Its Biosimilar
NCT04422171 ·Status: UNKNOWN
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
NCT03151551 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
NCT00647491 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity
NCT01610947 ·Status: COMPLETED ·Phase: NA
-
Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
NCT01559103 ·Status: TERMINATED ·Phase: PHASE1
-
Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
NCT00085644 ·Status: COMPLETED ·Phase: PHASE3
-
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
NCT02137226 ·Status: COMPLETED ·Phase: PHASE3
-
A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
NCT01502423 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
NCT01163916 ·Status: COMPLETED
-
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
NCT02121210 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
NCT01474876 ·Status: COMPLETED
-
An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid Arthritis
NCT05170646 ·Status: COMPLETED
-
Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab
NCT01752855 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
NCT02990806 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
NCT00779012 ·Status: COMPLETED ·Phase: PHASE4
-
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
NCT02116504 ·Status: UNKNOWN ·Phase: NA
-
Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.
NCT01561313 ·Status: COMPLETED ·Phase: PHASE2